Critical Survey: Tobira Development (TBRA) versus Sarepta Therapeutics (SRPT)

Tobira Development (NASDAQ: TBRA) and Sarepta Therapeutics (NASDAQ:SRPT) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Risk and Volatility

Tobira Development has a beta of -2.38, meaning that its stock price is 338% less volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500.

Valuation & Earnings

This table compares Tobira Development and Sarepta Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Tobira Development N/A N/A N/A ($3.08) -13.67
Sarepta Therapeutics $56.77 million 49.97 -$229.47 million ($2.45) -18.00

Tobira Development has higher revenue, but lower earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Tobira Development, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Tobira Development and Sarepta Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tobira Development N/A N/A -153.93%
Sarepta Therapeutics N/A -63.65% -52.75%

Institutional and Insider Ownership

62.4% of Tobira Development shares are held by institutional investors. Comparatively, 65.4% of Sarepta Therapeutics shares are held by institutional investors. 6.2% of Tobira Development shares are held by company insiders. Comparatively, 9.6% of Sarepta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for Tobira Development and Sarepta Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tobira Development 0 1 2 0 2.67
Sarepta Therapeutics 0 5 15 1 2.81

Tobira Development currently has a consensus price target of $130.67, indicating a potential upside of 210.45%. Sarepta Therapeutics has a consensus price target of $63.52, indicating a potential upside of 44.04%. Given Tobira Development’s higher probable upside, equities research analysts plainly believe Tobira Development is more favorable than Sarepta Therapeutics.

Summary

Sarepta Therapeutics beats Tobira Development on 9 of the 11 factors compared between the two stocks.

Tobira Development Company Profile

Tobira Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. The Company’s product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of C-C chemokine receptor type 2 (CCR2) and C-C chemokine receptor type 5 (CCR5) in late stage development for the treatment of NASH, a serious liver disease that can progress to cirrhosis, liver cancer and liver failure. CVC is also being investigated to address primary sclerosing cholangitis (PSC), a disease which causes inflammation and scarring of the bile ducts, eventually leading to liver damage. The Company’s pipeline also includes evogliptin, a selective dipeptidyl peptidase 4 (DPP-4) inhibitor, which it plans to develop for NASH in combination with CVC.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

Receive News & Ratings for Tobira Development Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tobira Development Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.